Krystal Biotech (KRYS) Non-Current Assets (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Non-Current Assets data on file, last reported at $377.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 22.63% year-over-year to $377.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 15.32% YoY), and the FY2025 full-year result was $309.2 million, down 1.47% from the prior year.
• Non-Current Assets improved to $377.2 million in Q1 2026, from $309.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $377.2 million in Q1 2026 to a low of $172.6 million in Q2 2022.
• A 5-year average of $246.7 million and a median of $234.9 million in 2024 frame the typical range for Non-Current Assets.
• Peak annual rise in Non-Current Assets reached 380.95% in 2022, while the deepest fall reached 5.08% in 2022.
• Tracing KRYS's Non-Current Assets over 5 years: stood at $174.7 million in 2022, then jumped by 31.93% to $230.4 million in 2023, then jumped by 36.17% to $313.8 million in 2024, then fell by 1.47% to $309.2 million in 2025, then rose by 22.0% to $377.2 million in 2026.
• Business Quant data shows KRYS's Non-Current Assets at $377.2 million in Q1 2026, $309.2 million in Q4 2025, and $314.4 million in Q3 2025.